Group 1 - Nutex Health Inc. held its Q1 2025 earnings conference call on May 14, 2025, at 10:30 AM ET [1] - The call was moderated by Jennifer Rodriguez, the Investor Relations Manager, and included key leaders such as Dr. Tom Vo, Jon Bates, Warren Hosseinion, and Josh DeTillio [3][4] - The discussion aimed to review the company's performance and outline future plans, with a focus on financial results, operational progress, and strategic direction [3][4] Group 2 - The conference call included forward-looking statements based on management's current expectations, which are subject to risks and uncertainties [5] - Non-GAAP measures like adjusted EBITDA were mentioned, with reconciliations available in the press release and Form 10-Q [5]

Nutex Health (NUTX) Q1 2025 Earnings Call May 14, 2025 10:30 AM ET Company Participants Jennifer Rodriguez - Investor & Public Relations ManagerTom Vo - CEO & Chairman of The BoardJon Bates - Chief Financial OfficerWarren Hosseinion - President & DirectorJoshua DeTillio - Chief Operating OfficerBill Sutherland - Director of ResearchThomas McGovern - Equity Research AssociateJoshua Cohen - Managing Partner Conference Call Participants Gene Mannheimer - Managing Director, Senior Research Analyst Operator Gree ...

Nutex Health (NUTX) Q1 2025 Earnings Call May 14, 2025 10:30 AM ET Speaker0 Greetings. Welcome to Newtek South First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in listen only mode. A question and answer session will follow the formal presentation. Please note, conference is being recorded. At this time, I'll turn the floor over to your host, Jennifer Rodriguez, Investor Relations for Newtek. Jennifer, you may begin. Speaker1 Good morning, everyone, and w ...

Core Viewpoint - Nutex Health Inc. reported strong financial results for Q1 2025, showcasing significant growth in revenue, net income, and operational efficiency, driven by increased hospital visits and successful arbitration efforts [4][6]. Financial Performance - Total revenue for Q1 2025 reached $211.8 million, a 213.8% increase from $67.5 million in Q1 2024 [9]. - Net income attributable to Nutex Health was $14.6 million, compared to a net loss of $0.4 million in Q1 2024 [9]. - Diluted earnings per share (EPS) improved to $2.56 from $(0.08) in Q1 2024 [9]. - EBITDA for Q1 2025 was $43.1 million, a 507.0% increase from $7.1 million in Q1 2024 [9]. - Adjusted EBITDA was $72.8 million, compared to $(0.4) million in Q1 2024 [9]. Operational Highlights - Total hospital division visits increased by 20.5% to 48,269 in Q1 2025, up from 40,068 in Q1 2024 [9]. - Revenue from mature hospitals rose by 186.5% in 2025 compared to 2024 [9]. - The arbitration process contributed approximately $105.0 million in additional revenue, accounting for 73.1% of the total revenue increase [9]. Cash Flow and Balance Sheet - Net cash from operating activities was $51.0 million for Q1 2025 [9]. - As of March 31, 2025, total assets were $761.9 million, with cash and cash equivalents of $87.7 million [10]. - Long-term debt stood at $21.7 million [10]. Stock-Based Compensation - Total stock-based compensation expense for Q1 2025 was $36.1 million, significantly higher than less than $0.1 million in Q1 2024 [9].

NUTEX HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS HOUSTON, TX − (PRNewswire) – MAY 13th, 2025 – Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced first quarter 2025 financial results for the three months ended March 31, 2025. "The great momentum that ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-41346 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 11-3363609 (State or ot ...

Core Viewpoint - Nutex Health Inc. will release its financial results for the first quarter ended March 31, 2025, on May 13, 2025, and will discuss these results in a conference call on May 14, 2025 [1] Company Overview - Nutex Health Inc. is headquartered in Houston, Texas, and was founded in 2011. It operates as a healthcare management and operations company with two main divisions: Hospital Division and Population Health Management Division [3] - The Hospital Division owns, develops, and operates innovative healthcare models, including 24 micro-hospitals across 11 states [3] - The Population Health Management Division manages provider networks such as Independent Physician Associations (IPAs) and offers management and administrative support services to affiliated hospitals and physician groups [4]

Company Overview - Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company [1] - The company reported Q4 results on March 31, 2025 [1] Financial Performance - Revenue for Q4 was $258 million, representing a year-over-year increase of 270% [1] - GAAP EPS for the quarter was $11.12 [1] - The stock performed well following the earnings report [1]

Financial Performance - For the full year of 2024, total revenue reached $479.9 million, up 94% from $247.6 million in 2023 [11] - Adjusted EBITDA increased from $10.8 million in 2023 to $123.7 million in 2024, representing an increase of over 1,000% [11] - Net income for 2024 was $52 million compared to a loss of $46 million in 2023 [12] - Total visits at the hospital increased by 17% from 144,000 in 2023 to 168,000 in 2024 [12] - Current portion of long-term debt increased slightly from $10.8 million in 2023 to $14 million in 2024, while net long-term debt decreased from $26 million to $22 million [13] Business Line Performance - In Q4 2024, total revenue grew 270% to $257.6 million compared to $69.7 million in Q4 2023, with arbitration contributing $169.7 million to this increase [29] - Mature hospitals saw a revenue increase of 175.6% in Q4 2024 compared to Q4 2023 [30] - The population health division's revenue increased by approximately 11% to $7.9 million in Q4 2024 from $7.1 million in Q4 2023 [31] Market Performance - The company opened four new hospitals in 2024, expanding its network to 24 hospitals across 11 states [23] - The company is targeting high-demand growth markets for future hospital openings, with plans for new facilities in 2025, 2026, 2027, and 2028 [24] Company Strategy and Industry Competition - The company is focused on increasing hospital volume, inpatient admissions, and revenue per patient through efficient revenue cycle processes like arbitration [26] - The company aims to adapt to industry disruptions, such as the No Surprises Act, and has successfully pivoted to leverage arbitration for better reimbursement rates [27] - The company is integrating AI tools to enhance operational efficiency and patient care [65] Management Commentary on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the adaptability and resilience of the company in navigating challenges [27] - The arbitration process has shown positive results, with an 80% win rate and significant increases in revenue per visit [21] - The company is committed to maintaining low costs and aggressive debt management while expanding its services [26] Other Important Information - Cash and cash equivalents increased to just under $44 million, up from $22 million in 2023, reflecting a 98.2% increase [45] - Accounts receivable rose to $232 million from $58.6 million at the end of 2023, largely due to the arbitration process [45] Q&A Session Summary Question: Prospective outlook on the arbitration process - Management indicated that arbitration is a tool to collect fair rates and will continue to be used as long as the No Surprises Act is in effect [74] - The company is monitoring the situation closely and expects to have more data as the year progresses [79] Question: Revenue recognition at the time of service - Revenue is recognized at the time of service, with adjustments made post-IDR adjudication based on historical data [94] Question: Spread of IDR amounts over quarters - The company plans to progressively update revenue recognition throughout 2025 based on ongoing data rather than back-loading it [104] Question: Performance of new hospitals - Two of the four new hospitals are performing better than expected, while the other two are meeting expectations [108] Question: Expectations for mature hospitals - The company aims for single-digit growth in ER volume year-over-year while also ramping up other service lines [114]

Core Insights - Nutex Health Inc. reported significant financial growth for the fiscal year 2024, with total revenue reaching $479.9 million, a 93.8% increase from $247.6 million in 2023 [5] - The company achieved a net income of $52.2 million compared to a net loss of $45.8 million in the previous year, marking a substantial turnaround [5] - The arbitration process initiated in July 2024 contributed approximately $169.7 million in additional revenue, accounting for 73.1% of the overall revenue increase [5][8] Financial Performance - Total revenue for the year ended December 31, 2024, was $479.9 million, up from $247.6 million in 2023, reflecting a growth of $232.3 million [5] - Net income for the year was $52.2 million, a significant improvement from the net loss of $45.8 million in 2023 [5] - EBITDA for the year was $98.4 million, compared to a negative EBITDA of $(22.5) million in 2023 [5] - Adjusted EBITDA reached $123.7 million, a remarkable increase of 1,045.4% from $10.8 million in 2023 [5] Quarterly Highlights - For the fourth quarter of 2024, total revenue was $257.6 million, a 269.6% increase from $69.7 million in the same quarter of 2023 [5] - Net income for the fourth quarter was $61.7 million, compared to a net loss of $31.7 million in the fourth quarter of 2023 [5] - Total visits at the Hospital Division increased by 16.9% year-over-year, with mature hospitals seeing a 6.5% increase in visits [5][7] Operational Metrics - The company operated 24 micro hospitals and outpatient departments across 11 states, focusing on integrated healthcare delivery [2][24] - The arbitration initiative has led to higher reimbursement amounts per visit, aligning more closely with fair market rates [8] - The company plans to continue optimizing operations and maintaining a lean cost structure to support sustained growth in 2025 [7]